StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Janumet (sitagliptin and metformin HCl) by Quarter

Janumet (sitagliptin and metformin HCl) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)

QuarterlyAnnual

Merck Janumet (sitagliptin and metformin HCl): -33.0% in Q2 2026, down 47.0 pts from a year earlier.

Latest, Q2 2026
-33.0%
Period ended Jun 30, 2026
Change on a year earlier
-47.0 pts
14.0% in Q2 2025
History
31 quarters
Since Q4 2017
Sources
31
Documents cited below

Where the Q2 2026 figure comes from

“|| Janumet | 207 | 171 | 378 | 247 | 251 | 498 | 243 | 199 | 940 | -32 | -33 | -24 | -25”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 8-K Table 3 / 10-K / 10-Q MD&A.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedJanumet (sitagliptin and metformin HCl) — Worldwide constant-currency (ex-exchange) growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 2026-33.0%-47.0 ptsForm 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 2025-22.0%-33.0 ptsForm 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202520.0%–Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 202514.0%+46.0 ptsForm 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q4 2024Dec 31, 202411.0%+43.0 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q2 2024Jun 30, 2024-32.0%-9.0 ptsForm 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2024Mar 31, 2024-20.0%+4.0 ptsForm 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2023Dec 31, 2023-32.0%–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2023Sep 30, 2023-38.0%-31.0 ptsForm 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗
Q2 2023Jun 30, 2023-23.0%-29.0 ptsForm 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗
Q1 2023Mar 31, 2023-24.0%-23.0 ptsForm 8-K (tm2313695d1_ex99-1.htm, filed 2023-04-27) ↗
Q3 2022Sep 30, 2022-7.0%-1.0 ptsForm 8-K (tm2227726d1_ex99-1.htm, filed 2022-10-27) ↗
Q2 2022Jun 30, 20226.0%+14.0 ptsForm 8-K (tm2221828d1_ex99-1.htm, filed 2022-07-28) ↗
Q1 2022Mar 31, 2022-1.0%+5.0 ptsForm 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗
Q4 2021Dec 31, 202110.0%+11.0 ptsForm 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
Q3 2021Sep 30, 2021-6.0%-2.0 ptsForm 8-K (tm2131077d1_ex99-1.htm, filed 2021-10-28) ↗

Cite this data

StockData. (2026). Merck Janumet (sitagliptin and metformin HCl) (%), quarterly Q4 2017–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-janumet-ww-exfx-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.